Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.37 |
| ▸ | NR1D1 | P20393 | 4/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8957471 | 0.94 | CA1 (0.38) | CTSSCTSKOPRK1OPRM1OPRD1 | |
| SCHEMBL8091529 | 0.94 | CTSS (0.39) | CTSSCTSKOPRK1OPRM1OPRD1 | |
| SCHEMBL3748687 | 0.89 | NR1D1 (0.36) | CTSSCTSKNR1D1NR1H3ACACB | |
| SCHEMBL8090953 | 0.89 | ATM (0.39) | CTSSCTSKOPRK1OPRM1OPRD1 | |
| SCHEMBL8957382 | 0.88 | CTSS (0.39) | CTSSCTSKOPRK1OPRM1OPRD1 | |
| SCHEMBL92706 | 0.86 | ACACB (0.38) | NR1D1ACACB | |
| SCHEMBL15044629 | 0.86 | ACACB (0.38) | NR1D1ACACB | |
| SCHEMBL7516386 | 0.86 | PTPN1 (0.41) | NR1D1ACACB | |
| SCHEMBL15388283 | 0.85 | NR1D1 (0.52) | NR1D1NR1H3 | |
| SCHEMBL8099090 | 0.85 | SMN1; SMN2 (0.44) | NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226578-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SHERING AG (DE) | 2007-06-05 | — | — | US | disclosed |
| US-6916461-B2 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2005-07-12 | — | — | US | disclosed |
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20030232012-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6468502-B1 | PARAMAGNETIC MACROMOLECULES WITH HIGHER PROTON RELAXIVITY; LOWER DOSAGE AND INCREASED SIGNAL INTENSITY; DETECTING VASCULAR DISEASES; DIFFERENTIATING TISSUE BLOOD SUPPLY LEVELS; DISTINGUISHING MYOCARDIAL INFARCTION FROM ISCHEMIA | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-22 | — | — | US | disclosed |
| US-6180113-B1 | USED IN TUMOR THERAPY AND INTERVENTIONAL RADIOLOGY | SCHERING AG (DE) | 2001-01-30 | — | — | US | disclosed |
| US-6039931-A | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-21 | — | — | US | disclosed |
| US-5798092-A | METAL COMPLEXES; CONTRAST AGENTS FOR MEDICAL IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-25 | — | — | US | disclosed |
| US-5695739-A | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| EP-0731784-A1 | ARYL HALIDE SUBSTITUTED METALLIC COMPLEXES, PHARMACEUTICALS CONTAINING THESE COMPLEXES, THEIR USE FOR DIAGNOSTIC PURPOSES, AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015306-A1 | ARYL HALIDE SUBSTITUTED METALLIC COMPLEXES, PHARMACEUTICALS CONTAINING THESE COMPLEXES, THEIR USE FOR DIAGNOSTIC PURPOSES, AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-06-08 | — | — | WO | disclosed |
| EP-0405704-B1 | DTPA-complexes derivatives, pharmaceutical compositions containing them, their use and process for their preparation | SCHERING AG (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0405704-A2 | DTPA-complexes derivatives, pharmaceutical compositions containing them, their use and process for their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147563-A1 | Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis | FABP1, FLOT1, AFF1 | CTSS 4016/4885CTSK 4243/4885OPRK1 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.